<SEC-DOCUMENT>0001140361-25-035251.txt : 20250917
<SEC-HEADER>0001140361-25-035251.hdr.sgml : 20250917
<ACCEPTANCE-DATETIME>20250917161550
ACCESSION NUMBER:		0001140361-25-035251
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250911
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250917
DATE AS OF CHANGE:		20250917

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ROCKET PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001281895
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36829
		FILM NUMBER:		251320189

	BUSINESS ADDRESS:	
		STREET 1:		350 FIFTH AVENUE
		STREET 2:		SUITE 7530
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10118
		BUSINESS PHONE:		646-440-9100

	MAIL ADDRESS:	
		STREET 1:		350 FIFTH AVENUE
		STREET 2:		SUITE 7530
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10118

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOTEK PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20040226
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ef20055707_form8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:cef="http://xbrl.sec.gov/cef/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:rckt="http://rocketpharma.com/20250911" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 25.9.1.5330
         Copyright 1995 - 2025 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_9bcfb881f8e94d74a5a027f1da2b1e53" contextRef="c20250911to20250911" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_06a43207b6ce4c0d988be10a32a069c8" contextRef="c20250911to20250911">0001281895</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_30b23652e8ee423595f74a59892f1be5" contextRef="c20250911to20250911">NJ</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="rckt-20250911.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20250911to20250911"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-09-11</xbrli:startDate><xbrli:endDate>2025-09-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
<div style="line-height: initial;">
  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
    <div> <br/>
    </div>

    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, DC 20549</div>

      <div><br/>
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_543cc8cde36c4bf18cfaa8a59359d0cd" contextRef="c20250911to20250911">8-K</ix:nonNumeric></div>

      <div><br/>
      </div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</div>

      <div><br/>
      </div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_93d2aee26f3443e9bbdb130030f8d6fc" contextRef="c20250911to20250911" format="ixt:date-monthname-day-year-en">September 11, 2025</ix:nonNumeric></div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/> </div>

      <div><br/>
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_0af8903f06904ffb86fd446d2b032f00" contextRef="c20250911to20250911">Rocket Pharmaceuticals, Inc.</ix:nonNumeric><br/>
      </div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(Exact name of registrant as specified in its charter)</div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/> </div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 33.3%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_77662285ac764c3988378b13d79742ef" contextRef="c20250911to20250911" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_d8069a2330b84b24b7e53e2d4f2294ea" contextRef="c20250911to20250911">001-36829</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 32.7%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_189912fd0d804b9dacd1b0d43cd69eb0" contextRef="c20250911to20250911">04-3475813</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 33.3%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(State or other jurisdiction of incorporation)</div>
            </td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(Commission File Number)</div>
            </td>

    <td style="width: 32.7%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(IRS Employer Identification No.)</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 49.93%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_f22ee553e2e44a959a8a108829e76a67" contextRef="c20250911to20250911">9 Cedarbrook Drive</ix:nonNumeric>,
                <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_e713e50c676b44f7ae07da274d27245c" contextRef="c20250911to20250911">Cranbury</ix:nonNumeric>, <span style="-sec-ix-hidden:Fact_30b23652e8ee423595f74a59892f1be5">NJ</span></div>
            </td>

    <td style="width: 49.93%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_ac0cdb1d754d4c2b9a11ecc5973be7cd" contextRef="c20250911to20250911">08512</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.93%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(</span>Address of principal executive offices)</div>
            </td>

    <td style="width: 49.93%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(Zip Code)</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      <div><br/>
      </div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric name="dei:CityAreaCode" id="Fact_339588db56884c908766063c7246977d" contextRef="c20250911to20250911">646</ix:nonNumeric>)
        <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_f3fe47ba63144baab0b1cae69d070eaf" contextRef="c20250911to20250911">440-9100</ix:nonNumeric></div>

      <div><br/>
      </div>

      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      <div><br/>
      </div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Not applicable</div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(Former name or former address, if changed since last report)</div>

      <div><br/>
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
        following provisions (see General Instruction A.2):</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_2aa0ea434fca473896c21f4911ef3c63" contextRef="c20250911to20250911" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_da7488ecc6b34320b8c343d784507648" contextRef="c20250911to20250911" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_8c3defdcfc3940018c783e94d8049b6c" contextRef="c20250911to20250911" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_48186a54a7a74c1eba6e2c97e9c3276c" contextRef="c20250911to20250911" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 32%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Title of each class</div>
            </td>

    <td style="width: 2.37%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>

    <td style="width: 32%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Trading</div>
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Symbol(s)</div>
            </td>

    <td style="width: 2.37%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>

    <td style="width: 32%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Name of each exchange on which</div>
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_173e410f99984b92bd302dc9809d9be5" contextRef="c20250911to20250911">Common stock, $0.01 par value</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 2.37%; vertical-align: top;">&#160;</td>

    <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_ecad95df0e2e449a9032f25aa73bd669" contextRef="c20250911to20250911">RCKT</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 2.37%; vertical-align: top;">&#160;</td>

    <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_436686f0c9cf4eb8820d422c99e3a363" contextRef="c20250911to20250911" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this
        chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</div>

      <div><br/>
      </div>

      <div style="text-align: right; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_173c626f573e4597b2567da370616b33" contextRef="c20250911to20250911" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

      <div><br/>
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
        or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-size: 10pt; font-family: 'Times New Roman';">&#9744;</span></div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/> </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 1.01.</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Entry into a Material Definitive Agreement</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In connection with the previously announced departure of Dr. Kinnari Patel to accept a role as a venture partner at RTW
          Investments LP, on September 11, 2025, Rocket Pharmaceuticals, Inc. (the &#8220;Company&#8221;) entered into a Separation and Release Agreement (the &#8220;Separation Agreement&#8221;) with Dr. Patel. Pursuant to the Separation Agreement, Dr. Patel agreed to a general
          release of claims in favor of the Company and its affiliates and agreed to certain restrictive covenants.</div>

      <div><br/>
      </div>

      <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Separation Agreement also provides for the following:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 54pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Dr. Patel shall be entitled to receive her current salary and medical, dental and vision coverage benefits through December 31, 2025 (the &#8220;Separation Date&#8221;) in accordance with
                regular payroll procedures and shall be paid for all accrued and unused paid time off as of the Separation Date;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 54pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Dr. Patel shall be entitled to receive a lump sum payment of $482,040, consistent with the Company&#8217;s Severance and Change in Control Program, provided that she deliver an executed
                release of claims (the &#8220;Release of Claims&#8221;) within seven days of the Separation Date;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 54pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">The Company shall offer Dr. Patel a Consulting Agreement to serve as a consultant to the Company beginning on the expiration of the revocation period provided for in the Release of
                Claims; and</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 54pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Dr. Patel shall be receive a lump sum healthcare allowance of $30,045, equal to the cost of COBRA premiums for ten (10) months.</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">On September 11, 2025, Dr. Patel and the Company entered into a Consulting Agreement to be effective beginning on the expiration of the revocation
        period provided for in the Release of Claims (the &#8220;Effective Date&#8221;). The Consulting Agreement shall begin on the Effective Date and continue through December 31, 2026 (the &#8220;Consulting Period&#8221;), unless earlier terminated by either party pursuant to
        the terms therein. The Company shall pay Dr. Patel an aggregate retainer fee of $582,156 under the Consulting Agreement and Dr. Patel shall provide such general consulting services as reasonably required by the Company. The Consulting Agreement
        also provides that Dr. Patel shall retain the restricted stock units and options through the Consulting Period granted under any and all Rocket Pharmaceuticals, Inc. Stock Option, Share Option, and Incentive Plans.</div>

      <div><br/>
      </div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The foregoing summaries of the Separation Agreement and Consulting Agreement are qualified in their entirety by reference to the text of the documents,
        which are filed as Exhibits 10.1 and 10.2 hereto, respectively, and incorporated herein by reference.</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 54pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Financial Statements and Exhibits.</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">(d) Exhibits</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="vertical-align: top; white-space: nowrap; width: 9.54%;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit No.</div>
            </td>

    <td style="width: 2.37%; vertical-align: top;">&#160;</td>

    <td style="width: 88.09%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Description</div>
            </td>

  </tr>

  <tr>

    <td style="width: 9.54%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a href="ef20055707_ex10-1.htm">10.1</a></div>
            </td>

    <td style="width: 2.37%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.09%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Separation and Release Agreement, dated as of September 11, 2025, by and between Rocket Pharmaceuticals, Inc. and Kinnari Patel.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 9.54%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a href="ef20055707_ex10-2.htm">10.2</a></div>
            </td>

    <td style="width: 2.37%; vertical-align: top;">&#160;</td>

    <td style="width: 88.09%; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Consulting Agreement, dated as of September 11, 2025, by and between Rocket Pharmaceuticals, Inc. and Kinnari Patel.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 9.54%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">104</div>
            </td>

    <td style="width: 2.37%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 88.09%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      </div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

      <div><br/>
      </div>

      <div style="text-align: left; text-indent: 20pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
        behalf by the undersigned hereunto duly authorized.</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="vertical-align: top;" colspan="2">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Rocket Pharmaceuticals, Inc.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 45%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Date: September 17, 2025</div>
            </td>

    <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">By:</div>
            </td>

    <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">/s/ Martin Wilson</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 45%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Martin Wilson</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 45%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">General Counsel and Chief Corporate Officer, SVP</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div><br/>
      </div>

      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    </div>

  </div>

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ef20055707_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 25.9.1.5330
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <!--PROfilePageNumberReset%Num%1%%%-->
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 10.1</font><br>
    </div>
    <div style="text-align: right;"><font style="font-weight: bold;"> <br>
      </font></div>
    <div style="text-align: center;"><img src="logo1.jpg"><font style="font-weight: bold;"> </font></div>
    <div> <br>
    </div>
    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Hlk208476189"></a>Rocket Pharmaceuticals, Inc.</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">9 Cedarbrook Drive</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Cranbury, NJ 08512</div>
      <div><br>
      </div>
      <div style="text-align: center; text-indent: 36pt; margin-left: 288pt; font-family: 'Times New Roman'; font-size: 10pt;">September 11, 2025</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Kinnari Patel</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">*******<br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">*******<br>
      </div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Dear Kinnari:</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">This letter (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Agreement and Release</u></font>&#8221;) confirms our agreement with
        regard to the resignation of your employment with Rocket Pharmaceuticals, Inc. (&#8220;the <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Company</u></font>&#8221;) effective December 31, 2025 (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Separation Date</u></font>&#8221;). For avoidance of doubt, your last working day with the Company was August 8, 2025 (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Last Working Day</u></font>&#8221;).
        During the period between the Last Working Day and the Separation Date (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Garden Leave Period</u></font>&#8221;), you shall be on paid garden leave and your employment with the Company
        will terminate at the end of the Garden Leave Period on the Separation Date. During the Garden Leave Period, you shall remain employed by the Company but shall not report to the Company&#8217;s office or perform any work for the Company unless
        specifically instructed to do so by the Company. You shall continue to receive base pay and benefits during the Garden Leave Period at the same level you were receiving on the Last Working Day.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Notwithstanding the terms of your Severance and Change In Control Agreement, dated October 26, 2018 (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Severance Agreement</u></font>&#8221;), our complete understanding and agreement with respect to your separation from the Company is described below.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z820eff36e9e74455be324c827eac2790" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Unconditional Payments</u></font>. Your total unconditional compensation, payments and benefits from the Company
                shall be as follows:</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; You will receive your final pay through the Separation Date, less applicable statutory deductions, and authorized withholdings.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;You will be paid for all accrued but unused paid time off as of the Separation Date (calculated to be $102,480), less applicable
        statutory deductions and authorized withholdings.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">c.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; You will receive reimbursement for unreimbursed business expenses properly incurred by you, which shall be subject to and paid in
        accordance with the Company's expense reimbursement policy.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">1</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">d.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; You will receive, under separate cover, information about your rights to elect medical, dental, and vision insurance continuation
        coverage under the Consolidated Omnibus Budget Reconciliation Act (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>COBRA</u></font>&#8221;).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Nothing in this Agreement and Release is intended to impair any of the rights described in this Section 1.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Separation Payment</u></font>. Provided that you agree to and accept
        the terms of this Agreement and Release, and provided further that you execute the Release of Claims attached hereto as <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exhibit A</u></font> during the 7-day period after the
        Separation Date and do not thereafter timely revoke it:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Consistent with the Company&#8217;s Severance and Change in Control Program, you will receive a lump sum payment equal to ten (10) months of
        your current salary, calculated to be $482,040, less required statutory tax deductions and authorized withholdings, payable upon the Company&#8217;s next regular payroll date following the Separation Date, the Company&#8217;s receipt of the signed Release of
        Claims and the completion of the revocation period provided for in the Release of Claims.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall offer you a Consulting Agreement in the form attached hereto as <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exhibit B</u></font> (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Consulting Agreement</u></font>&#8221;), which will not become effective until the expiration of the revocation period provided for in the Release
        of Claims.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">c.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; You will remain eligible for a 2025 annual bonus based on the Company&#8217;s actual financial results for 2025, as determined by the Company&#8217;s
        Compensation Committee, and subject to the Company&#8217;s annual corporate multiplier, less applicable withholdings and deductions. Any 2025 bonus is payable at the same time bonuses are paid to continuing employees of the Company in 2026.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">d.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Your medical, dental and vision coverage (if applicable) will remain in effect until December 31, 2025. On January 1, 2026, you will
        become eligible to elect continuing coverage under COBRA.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">e.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; You will receive a lump sum health care allowance of $30,045.22, equal to the cost of your COBRA premiums for ten (10) months, less
        required statutory tax deductions and authorized withholdings, payable upon on the Company&#8217;s next regular payroll date following the Separation Date, the Company&#8217;s receipt of the signed Release of Claims and the completion of the revocation period
        provided for in the Release of Claims.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">f.&#160;&#160;&#160;&#160; &#160; &#160;&#160; The benefits provided in Section 2 above are referred to in this Agreement and Release as the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Separation Payment</u></font>.&#8221;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">g.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Your eligibility to receive and retain the Separation Payment is expressly contingent upon your compliance with each and every provision
        of this Agreement and Release, including without limitation your compliance with Sections 9, 10, 11, 12 and 13. If you fail to comply with this Agreement and Release, including without limitation Sections 9, 10, 11, 12 and 13, you hereby
        acknowledge and agree that the Company&#8217;s obligation to provide the payments and benefits set forth in this Agreement shall immediately cease, you shall reimburse the Company the full Separation Payment and the Company shall be entitled to seek any
        and all rights and remedies under applicable law.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">3.&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Legal Fees.</u></font> Company shall promptly pay, upon receiving an
        invoice therefore, all reasonable fees, charges and disbursements of Cohen &amp; Buckman P.C. and Squire Patton Boggs (US) LLP, counsel to the Consultant incurred in connection with Consultant&#8217;s separation of employment.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Benefits</u></font>. You retain your right to benefits that you have
        earned and to which you are entitled through the end of the month in which you separate from the Company under the specific terms of those plans. To the extent permitted under the Company's Directors and Officers insurance policy (&#8220;D&amp;O
        Policy&#8221;), you qualify as a resigned insurance person. Per the D&amp;O Policy, a retired and resigned insured person&#8217;s extension period means an unlimited period following the end of the policy period in respect of matters first made, commenced or
        received and reported to the insurance company during such unlimited period. You will receive, under separate cover, information concerning your eligibility to continue health care benefits under COBRA.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>No Additional Benefits</u></font>. Other than as set forth in this
        Agreement and Release, you expressly acknowledge and agree that you are not entitled to and will not receive any additional compensation, payments, or benefits of any kind from the Company and the Releasees (as that term is defined in Section 7(b)
        below) and that no representations or promises to the contrary have been made to you.</div>
      <div><br>
      </div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">6.&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Unemployment</u></font>. The Company will not object to any lawful
        application by you to receive unemployment benefits.</div>
      <div><br>
      </div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">7.&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Release of Claims</u></font>.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; As a condition of the Company&#8217;s willingness to enter into this Agreement and Release, and in consideration for the Separation Payment
        and the agreements of the Company contained in this Agreement and Release, you, with the intention of binding yourself, your heirs, beneficiaries, trustees, administrators, executors, assigns and legal representatives (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Releasors</u></font>&#8221;), hereby release, waive and forever discharge the Company and the Releasees from, and hereby acknowledge full accord and satisfaction of, any and all claims,
        demands, causes of action, and liabilities of any kind whatsoever (upon any legal or equitable theory, whether contractual, common law or statutory, under federal, state or local law or otherwise), whether known or unknown, asserted or unasserted,
        by reason of any act, omission, transaction, agreement or occurrence that you ever had, now have or hereafter may have against the Company and the Releasees up to and including the date of the execution of this Agreement and Release.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">Without limiting the generality of the foregoing, the Releasors hereby release and forever discharge the Company and the Releasees from:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z7264ae5ec90b44ad85a2b9aad22ed4bb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 99pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">i.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">any and all claims relating to or arising from your employment with the Company, the terms and conditions of that employment, and the termination of that employment.</div>
            </td>
          </tr>

      </table>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zc9e78488b0aa4322ba7faa399e943921" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 99pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">ii.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">any and all claims of employment discrimination, harassment or retaliation under any federal, state or local statute or ordinance, public policy or the common law, including,
                without limitation, any and all claims under Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Americans with Disabilities Act, the Rehabilitation Act of 1973, the Age Discrimination in Employment Act, the Older
                Workers Benefit Protection Act, the Fair Labor Standards Act, the Equal Pay Act, the Sarbanes-Oxley Act, the Family Medical Leave Act, the Health Insurance Portability and Accountability Act of 1966, the National Labor Relations Act, the
                Occupational Safety and Health Act, the Genetic Information Nondiscrimination Act, the New Jersey Law Against Discrimination, the New Jersey Family Leave Act, the New Jersey Conscientious Employee Protection Act, the Millville Dallas
                Airmotive Plant Job Loss Notification Act, the New York State Civil Rights Law, the New York State Human Rights Law, the New York State Labor Law, the New York State Equal Pay Law, the New York Whistleblower Law, the New York Worker
                Adjustment and Retraining Notification Act, Section 125 of the New York Workers&#8217; Compensation Law, Article 23-A of the New York State Corrections Law together with the New York Executive Law &#167; 296(15), the New York City Human Rights Law,
                the New York City Earned Sick Time Act, as such laws have been or may be amended;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z6cc20eb0fc74489f91c4a7ef1ace5ca5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 99pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">iii.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">any and all claims for employee benefits, including, without limitation, any and all claims under the Employee Retirement Income Security Act of 1974, as amended; provided,
                however, that nothing in this Section 7 is intended to release, diminish, or otherwise affect any vested monies or other vested benefits to which you may be entitled from, under, or pursuant to any savings or retirement plan of the Company;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z11915ed3c38449d1b3aa98243cfc7518" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 99pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">iv.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">all claims for slander, libel, defamation, negligent or intentional infliction of emotional distress, personal injury, prima facie tort, negligence, compensatory or punitive
                damages, or any other claim for damages or injury of any kind whatsoever; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zb5f56d43b6c745be9556e3e17ecb6f5c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 99pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">v.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">any and all claims for monetary recovery, including, without limitation, attorneys&#8217; fees, experts&#8217; fees, medical fees or expenses, costs and disbursements and the like.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">By entering into this Agreement and Release, you represent and agree that the failure of this Agreement and Release to specifically identify or
        enumerate above any statute or common law theory under which you release claims is not intended by you or the Company to limit, diminish or impair in any way your intended and actual release all claims, demands, causes of action, and liabilities of
        any kind whatsoever against the Company and the Releasees.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">b.&#160;&#160;&#160;&#160;&#160;&#160; For purposes of this Agreement and Release, the term &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>the Company and the
            Releasees</u></font>&#8221; includes Rocket Pharmaceuticals, Inc. and its parents, subsidiaries, predecessors, direct and indirect affiliates, related companies, successors and assigns, regardless of the jurisdiction in which such entities may be
        located, and all of its and their respective past, present and future investors, directors, employees, partners, representatives and agents, whether acting as agents or in their individual capacities, and this Agreement and Release shall inure to
        the benefit of and shall be binding and enforceable by all such entities and individuals.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">c.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;It is understood that this release does not serve to waive any rights or claims that, pursuant to law, cannot be waived or subject to a
        release of this kind, such as: (i) claims for unemployment or workers&#8217; compensation benefits; (ii) rights to vested benefits under any applicable welfare, retirement and/or pension plans; (iii) rights to defense and indemnification, if any, from
        the Company for actions taken by Employee in the course and scope of her employment with the Company; (iv) claims, actions, or rights arising under or to enforce the terms of this Agreement and Release; and/or (v) the right to file a charge with an
        administrative agency or participate in an agency investigation; provided, however, that you hereby waive your right to recover any money in connection with such charge or investigation. Moreover, nothing in this Agreement and Release limits or
        waives, or is intended to limit or waive, your right pursuant to the Older Workers Benefit Protection Act to seek a judicial determination of the validity of the Agreement and Release&#8217;s waiver of claims under the Age Discrimination in Employment
        Act. This Agreement and Release is not intended to restrict your communications or actions that are protected by federal law, including discussing terms and conditions of employment or otherwise exercising protected rights under Section 7 of the
        National Labor Relations Act. This Agreement and Release does not limit your right to receive an award for information provided to the U.S. Securities and Exchange Commission.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">8.&#160;&#160;&#160;&#160;&#160;&#160; &#160;<u></u><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Separation from Employment</u></font>. By entering into this
        Agreement and Release, you acknowledge and agree that your employment with the Company has been severed. You agree that the Company shall not have any obligation at any time in the future to reemploy you or enter into any other business arrangement
        of any kind with you.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Company Property and Information</u></font>.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;You agree to return to the Company immediately upon the Last Working Date any and all Company property in your possession, custody or
        control including, but not limited to, any laptop(s), phone(s), charger(s), monitor(s), etc. and any and all original and duplicate copies of your work product and of files, calendars, books, employee handbooks, records, notes, notebooks, manuals,
        flash drive or any other form of electronic data storage device you have in your possession or under your control belonging to the Company, or containing confidential or proprietary information concerning the Company, and its partners, employees,
        consultants or operations. By signing this Agreement and Release, you confirm that you will not retain in your possession or under your control any of the documents or materials described in this Section 9(a), and that you will not be entitled to
        receive any installment of the Separation Payment unless and until all such documents and materials are returned to the Company. Notwithstanding the foregoing, during the term of the Consulting Agreement, you may keep and continue to use the
        Company issued laptop and cellular phone.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;With the exception of materials needed for services performed pursuant to the Consulting Agreement, you further agree that you will
        certify in writing to the Company, within three (3) days of the date you execute this Agreement and Release, that you have not retained and are not retaining any of the foregoing materials through any form of cloud computing storage, personal email
        account, or any other means of storing electronic information. You further agree that the Company may inspect on demand any Company issued electronic device, medium, or means of electronic storage in your possession or under your control on which
        Company confidential information is maintained, stored or retrieved, such inspection to be conducted by a neutral, third-party forensic specialist; and you further consent and agree to the jurisdiction of a court of competent jurisdiction in which
        an application for emergency relief is brought by the Company to enforce its rights under this Section 9. No inspection by any forensic specialist may be undertaken unless the privacy of any personal information that may be on such devices or in
        such electronic storage is adequately protected from disclosure to the Company.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">5</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">c.&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; You acknowledge that, while employed by the Company, you had access to and possessed information and materials that are not publicly
        available, including, without limitation, information and materials concerning the Company&#8217;s and its owner&#8217;s proprietary information, marketing, advertising and promotional ideas and strategies, marketing surveys and analyses, technology, budgets,
        business plans, customer or supplier lists, research or financial, purchasing, planning, employment or personnel data or information business and technical information, marketing plans, research, designs, customer information, plans, methods,
        techniques, processes and know-how, whether tangible or intangible and whether or not stored, compiled or memorialized physically, electronically or graphically or in writing (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Confidential


            Information</u></font>&#8221;). Accordingly, you agree never to use or disclose Confidential Information before it has become publicly known, through no fault of your own, unless required by law. You also agree that, if you are ever asked to disclose
        any Confidential Information pursuant to legal process or otherwise, you will immediately contact Martin Wilson, General Counsel and Chief Corporate Officer (legal@rocketpharma.com) to seek the Company&#8217;s express written consent to such disclosure
        prior to such disclosure.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">d.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; You acknowledge and agree that any breach or threatened breach of any of the provisions of this Section 9 would cause the Company and the
        Releasees irreparable harm not readily susceptible to measurement in economic terms or for which economic compensation may be inadequate. Accordingly, you agree that in the event of a breach or threatened breach by you of any of the provisions of
        this Section 9, the Company and the Releasees (and any potentially or actually irreparably harmed third-party beneficiaries) shall, in addition to any other legal remedies available to them, be entitled to equitable relief, including, without
        limitation, specific performance, a temporary restraining order(s), and temporary or permanent injunctive relief.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Restrictive Covenant Remains in Full Force and Effect</u></font>. You
        understand and agree that you remain fully bound by each and every provision of the Proprietary Information, Inventions and Non-Solicitation/Non-Competition Agreement (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Restrictive


            Covenant</u></font>&#8221;) between you and the Company and that, in addition to the good and valuable consideration you received in return for the Restrictive Covenant at the time you signed it, the Separation Payment constitutes good and valuable
        consideration for the continuing effectiveness of the Restrictive Covenant. For the avoidance of doubt, the Restrictive Covenant is intended to restrict employment with entities that are engaged in the commercialization or development of products
        that were provided or under development at the time of your employment with the Company.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">6</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Intellectual Property</u></font>.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; You agree that, at any time following the Separation Date, you do not have and will not claim any right, title or interest in any trade
        name, trademark, patent, copyright, work for hire or other similar rights belonging to or used by the Company and will not have or claim any right, title or interest in any material or matter of any sort prepared for or used in connection with the
        business or promotion of the Company, whatever your involvement with such matters may have been, and whether procured, produced, prepared, or published in whole or in part by you. You further recognize and agree that the Company now has and will
        hereafter have and retain the sole and exclusive rights in any and all such trade names, trademarks, patents, copyrights (all your work in this regard being a work for hire for the Company under the copyright laws of the United States), material
        and matter as described above. If any work created by you is not a work for hire under the copyright laws of the United States, then you hereby assign to the Company all rights, title and interests in each such work (including, but not limited to,
        copyrights rights). You agree that you will cooperate fully with the Company at all times following the Separation Date in the securing of any trade name, trademark, patent or copyright protection or other similar rights in the United States and in
        foreign countries and will give evidence and testimony and execute and deliver to the Company all papers requested by it in connection therewith. You hereby irrevocably appoint the Company as your attorney-in-fact (with a power coupled with an
        interest) to execute any and all documents which may be necessary or appropriate in the security of such rights, including but not limited to, any copyright in your work.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The fact that any work subject to copyright or patent protection under any applicable law created by you outside of the Company&#8217;s
        facilities or other than during your working hours with the Company does not diminish the Company&#8217;s rights with respect to such works. You agree to execute and deliver to the Company such further instruments or documents as may be requested by the
        Company in order to effectuate the purposes of this Section upon demand by the Company.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">c.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall have no rights pursuant to this Agreement and Release in any invention of Employee made during the term of your
        employment by the Company if such invention has not arisen out of or by reason of Employee&#8217;s work with the Company or does not relate to the products, business or operations of the Company or of its affiliated companies or joint ventures, although
        Employee shall nonetheless inform the Company of any such invention.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Confidentiality of Agreement and Release</u></font>. You agree that,
        except as hereinafter provided, you will keep the terms, conditions, and existence of this Agreement and Release in strict confidence and shall not disclose them to anyone except: (a) as may be reasonably necessary to enforce this Agreement and
        Release; (b) to you attorneys and bona fide tax advisors (provided that they agree to abide by the provisions of this Agreement and Release); (c) to your spouse, provided that your spouse agrees to abide by the provisions of this Agreement and
        Release; and (d) pursuant to compulsory legal process or a court order. There shall be no other disclosure by you except upon and to the extent of prior written permission from the Company.</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">7</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Mutual Nondisparagement and Employment References</u></font>.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; You agree that you will not disparage or encourage or induce others to disparage the Company and the Releasees. Without limiting the
        generality of the foregoing, you further agree that you will make no statements or take any action intended to, or that could reasonably be expected to, limit or impair the Company&#8217;s opportunities to combine, merge or acquire other businesses. With
        respect to the Company, &#8220;disparage&#8221; includes, without limitation, comments or statements to any person or entity, including but not limited to the press and/or media, or any entity with whom the Company and the Releasees, or any of them, has a
        business relationship, including any federal, state or local government agencies, which would adversely affect in any manner (a) the conduct of the business of the Company and the Releasees or (b) the reputation of the Company and the Releasees.
        &#8220;Disparage&#8221; includes, without limitation, comments or statements to any person or entity, including but not limited to the press and/or media, or any entity with whom you have a personal or business relationship, which would adversely affect in any
        manner your personal or professional reputation. The foregoing does not apply to pleadings, allegations, or other statements made in connection with a claim which is not being released by this Agreement and Release.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160; Likewise, Company agrees that its Executive Leadership Team and Board of Directors shall not disparage or encourage or induce others to
        disparage you during their period of employment and/or association with the Company. Without limiting the generality of the foregoing, you further agree that the Company Executive Leadership Team and Board of Directors will make no statements or
        take any action intended to, or that could reasonably be expected to, limit or impair the your opportunities to work with other businesses. With respect to the you, &#8220;disparage&#8221; includes, without limitation, comments or statements to any person or
        entity, including but not limited to the press and/or media, or any entity with whom the you have a business relationship, including any federal, state or local government agencies, which would adversely affect in any manner (a) your ability to
        conduct business or (b) your reputation. The foregoing does not apply to pleadings, allegations, or other statements made in connection with a claim which is not being released by this Agreement and Release. Should any prospective employer contact
        the Company for professional references with regard to prospective employment or otherwise, the Company will: (i) confirm the positions you held while employed by the Company; (ii) verify the dates of your employment with the Company; (iii) if
        requested, provide your rate of compensation with the Company as of the Separation Date. The Company and you agree to draft and consider a joint press release about your accomplishments and contributions to be released on Separation Date.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Consultation on Behalf of Company</u></font>. You agree that, upon
        request, you will cooperate and consult with the Company and the Releasees with respect to any inquiries or other matters involving them, including pending or threatened transactions, litigation, administrative proceedings or arbitration, (a) in
        which you were involved, (b) concerning which you have personal knowledge, or (c) that relate to or arise out of your employment with the Company and your responsibilities with respect to the Company and the Releasees, or any of them. Such
        cooperation and consultation will include, without limitation, appearance or attendance at any meetings or proceedings relating to any such inquiries, matters or proceedings; making yourself available for the purpose of answering interrogatories;
        being deposed; testifying at trial or otherwise; and preparing and signing affidavits; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>provided</u></font>, however, that the Company will pay your reasonable travel expenses for
        such appearance or attendance, and will not otherwise be obligated to remunerate your cooperation under this Section 14. Notwithstanding the foregoing, the Company agrees to reimburse you at not more than your hourly rate as of December 31, 2025,
        for any documented loss of wages you incur in providing cooperation and consultation to the company after the Separation Date.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">8</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Section 409A</u></font>.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement is intended to comply with &#167; 409A of the Internal Revenue Code of 1986, as amended (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Code</u></font>&#8221;) or an exemption thereunder and shall be construed and administered in accordance with Code &#167; 409A. Notwithstanding any other provision of this Agreement, payments provided under Section 2 of
        this Agreement may only be made upon an event and in a manner that complies with Code &#167; 409A or an applicable exemption. Any payments under this Agreement that may be excluded from Code &#167; 409A either as separation pay due to an involuntary
        separation from service or as a short-term deferral shall be excluded from Code &#167; 409A to the maximum extent possible. Any payments to be made under this Agreement upon a termination of employment shall only be made upon a &#8220;separation from service&#8221;
        under Code &#167; 409A. To the extent that any payment under Section 2 of this Agreement constitutes nonqualified deferred compensation under Code &#167; 409A and the period for providing and not revoking a release as set forth in Section 2 spans two
        calendar years, such payment shall not be paid until the second calendar year. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement comply with Code &#167; 409A and in no event
        shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by you on account of non-compliance with Code &#167; 409A.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding any other provision of this Agreement, if any payment or benefit provided to you in connection with your termination of
        employment is determined to constitute &#8220;nonqualified deferred compensation&#8221; within the meaning of Code &#167; 409A and you are determined to be a &#8220;specified employee&#8221; as defined in Code &#167; 409A(a)(2)(b)(i), then such payment or benefit shall not be paid
        until the first payroll date to occur following the six-month anniversary of the Separation Date or, if earlier, on your death (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Specified Employee Payment Date</u></font>&#8221;). The
        aggregate of any payments that would otherwise have been paid before the Specified Employee Payment Date shall be paid to you in a lump sum on the Specified Employee Payment Date and thereafter, any remaining payments shall be paid without delay in
        accordance with their original schedule.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Severability</u></font>. If at any time after the date of the
        execution of this Agreement and Release any provision of this Agreement and Release shall be held by any court of competent jurisdiction to be illegal, void or unenforceable, such provision shall be of no force and effect. The illegality or
        unenforceability of such provision shall have no effect upon, and shall not impair the enforceability of, any other provision of this Agreement and Release, provided, however, that if Section 7(a) is held to be illegal, void or unenforceable in
        whole or in part, you agree to promptly execute a valid general release and waiver in favor of the Company and the Releasees.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">9</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">17.&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Voluntary Agreement</u></font>. You acknowledge that before signing this
        Agreement and Release, you carefully reviewed this Agreement and Release, the Company provided you with at least twenty-one (21) days to review this Agreement and Release, and that you are entering into it voluntarily and of your own free will. You
        acknowledge that even after signing this Agreement and Release, you may revoke your acceptance to the terms of this Agreement for up to seven (7) days following the date of your acceptance. Please provide your revocation in writing to the People
        Team at people@rocketpharma.com.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">18.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>No Admission</u></font>. You understand and agree that the making of
        this Agreement and Release is not intended, and shall not be construed, as an admission that the Company and the Releasees, or any person now or previously employed by or associated with the Company and the Releasees, have violated any federal,
        state or local law, ordinance, regulation, public policy or common law rule, or have committed any wrong whatsoever against you. In addition to the confidentiality provisions set forth in Section 9 above, and not by way of limitation thereof, this
        Agreement and Release shall be deemed to fall within the protection afforded to settlements, compromises and offers to compromise by applicable law.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">19.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Complete Agreement</u></font>. This Agreement and Release represents
        the complete understanding between you and the Company concerning the subject matter of this Agreement and Release, and no other promises or agreements concerning the subject matter of this Agreement and Release shall be binding unless reduced to
        writing and signed by you and the Company; provided, however, that the Restrictive Covenant remains in full force and effect. You and the Company agree that this Agreement and Release supersedes any prior agreements or understandings of the
        parties, whether oral or written, concerning the subject matter of this Agreement and Release.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">20.&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Drafting</u></font>. Should any provision of this Agreement and
        Release require interpretation or construction, it is agreed by you and the Company that the person interpreting or construing this Agreement and Release shall not apply a presumption against one party by reason of the rule of construction that a
        document is to be construed more strictly against the party who prepared the document.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">21.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Successors and Assigns</u></font>. This Agreement and Release is
        binding upon, and shall inure to the benefit of, the Company and the Releasees, and its and their respective heirs, executors, administrators, successors and assigns.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">22.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Governing Law</u></font>. This Agreement and Release is governed by
        the laws of the State of New York, regardless of your work location or place of residence at any time during your employment by the Company and irrespective of the principles of conflicts of law. You and the Company hereby agree that any action to
        enforce or interpret this agreement shall be brought in a federal or state court of competent jurisdiction in New York, and you hereby irrevocably consent to the jurisdiction of such court.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">If this Agreement and Release is acceptable to you, please indicate your agreement by signing and dating below.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">10</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zcb1853621bdb47ad8846df3ba241f481" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td colspan="2" rowspan="1" style="width: 5%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Sincerely,</div>
            </td>
          </tr>
          <tr>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td colspan="2" rowspan="1" style="width: 5%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">ROCKET PHARMACEUTICALS, INC.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">By:</div>
            </td>
            <td style="width: 50%; vertical-align: top; border-bottom: 2px solid black;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">/s/ Martin Wilson</div>
            </td>
          </tr>
          <tr>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Martin Wilson</div>
            </td>
          </tr>
          <tr>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">General Counsel and Chief Corporate Officer</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">READ THIS AGREEMENT AND CAREFULLY CONSIDER ALL OF ITS PROVISIONS BEFORE SIGNING IT; IT HAS IMPORTANT LEGAL CONSEQUENCES AND INCLUDES A GENERAL
        RELEASE AND WAIVER OF KNOWN AND UNKNOWN CLAIMS. CONSULT YOUR ATTORNEY BEFORE SIGNING IT.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">I acknowledge that I have read this Agreement and Release and that I understand and voluntarily accept its terms.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zf0f1ec0f98c543f0a5dcbe85ae6bfd8c" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top; border-bottom: 2px solid black;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">/s/ Kinnari Patel</div>
            </td>
            <td colspan="1" style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Date:</div>
            </td>
            <td style="width: 35%; vertical-align: top; border-bottom: 2px solid black;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">9/11/2025</div>
            </td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160; Kinnari Patel</div>
            </td>
            <td colspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 35%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">11</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>EXHIBIT A</u></div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">RELEASE OF CLAIMS</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">[<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">To be signed and dated during the 7-day period following the
          Separation Date</font>]</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This Release of Claims, dated as of the ___ day of ______ 202_ (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Release Date</u></font>&#8221;),


        is provided by Kinnari Patel (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Releasor</u></font>&#8221;) in favor of the Company and the Releasees as that term is defined in the Agreement and Release between Releasor and Rocket
        Pharmaceuticals, Inc. (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Company</u></font>&#8221;) dated as of the _________ (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Release</u></font>&#8221;). Capitalized
        terms used herein but not defined have the meanings ascribed to them in the Release.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In exchange for the consideration set forth in paragraph 2 of the Release, Releasor hereby releases the Company and the Releasees from all claims
        and rights that Releasor has or may have against any and all of the Company and the Releasees, including, but not limited to, those claims of which Releasor is not aware, those not mentioned in this Release of Claims, and all claims for attorneys&#8217;
        fees, costs, and interest. This Release of Claims is a general release of claims and applies to claims and rights resulting from anything that has happened up to and including the Release Date. This Release of Claims does not apply to claims
        arising after the Release Date or to any rights provided to Releasor under the Release.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Releasor specifically releases all claims and rights arising from or relating to Releasor&#8217;s employment or other relationship with the Company and
        the Releasees and the termination of that employment, including but not limited to any claims or rights Releasor may have under Title VII of the Civil Rights Act of 1964, as amended, and the Civil Rights Act of 1991, the Age Discrimination in
        Employment Act, as amended, the Older Workers Benefit Protection Act, the Americans with Disabilities Act, as amended, the Rehabilitation Act of 1973, the federal Family and Medical Leave Act, Section 1981 of the Civil Rights Act of 1866, <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">the Uniformed Services Employment and Reemployment Rights Act of 1994, </font>the federal Worker Adjustment and Retraining Notification Act, the Employee Retirement Income
        Security Act of 1974, as amended, the federal Equal Pay Act, the Consolidated Omnibus Budget Reconciliation Act, the Occupational Safety and Health Act of 1970, the Fair Credit Reporting Act, the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall
        Street Reform and Consumer Protection Act, the New Jersey Law Against Discrimination, the New Jersey Family Leave Act, the New Jersey Conscientious Employee Protection Act, the Millville Dallas Airmotive Plant Job Loss Notification Act, the New
        York State Civil Rights Law, the New York State Human Rights Law, the New York State Labor Law, the New York State Equal Pay Law, the New York Whistleblower Law, the New York Worker Adjustment and Retraining Notification Act, Section 125 of the New
        York Workers&#8217; Compensation Law, Article 23-A of the New York State Corrections Law together with the New York Executive Law &#167; 296(15), the New York City Human Rights Law, the New York City Earned Sick Time Act, any other federal, state, local or
        foreign laws against discrimination, or any other federal, state, local or foreign law or common law relating to employment, wages, hours, or any other terms and conditions of employment; and Releasor releases any claims against the Company and the
        Releasees for retaliation, breach of implied covenant of good faith and fair dealing, promissory estoppel, intentional infliction of emotional distress, negligent infliction of emotional distress, wrongful discharge, tortious termination in
        violation of public policy, breach of contract, severance, short-term disability benefits, long-term disability benefits, defamation, malicious prosecution, tortious interference, fraudulent misrepresentation, negligent misrepresentation, unfair
        business practices, torts, assault, equitable relief or any other claims that Releasor now has or may have had, or hereafter claims to have, on behalf of Releasor or any other persons or entities, at any time, arising out of or relating to any acts
        or omissions done or occurring prior to and including the Release Date. Releasor specifically acknowledges and agrees that Releasor has been paid all sums earned by Releasor as a result of employment by any of the Releasees, that Releasor has
        received all business expense reimbursements to which Releasor is entitled as a result of employment by any of the Company and the Releasees, and that Releasor is not owed any sums whatsoever as a result of employment by any of the Company and the
        Releasees. Releasor also specifically acknowledges and agrees that the consideration set forth in paragraph 2 of the Release is money to which Releasor is otherwise not entitled except by signing the Release and this Release of Claims.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">12</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%%%-->
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Releasor warrants and represents that Releasor has not filed any complaint or charge of discrimination against any or all of the Company and the
        Releasees with any federal, state, local or foreign court, tribunal or administrative agency <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">(other than any claims or charges protected under the whistleblower
          provisions of federal law or regulations)</font>. In the event Releasor&#8217;s warranty and representation is false, Releasor shall be obligated to return the consideration set forth in paragraph 2 of the Release to the Company. Nothing in this
        Release of Claims prohibits Releasor from filing a new complaint with or providing information to the United States Equal Employment Opportunity Commission, the National Labor Relations Board, the U.S. Securities and Exchange Commission, or any
        similar state or local administrative agency, without prior authorization from the Company; provided, however, that if any such charge or complaint is filed or if any other person, organization or entity shall file such a charge, complaint or
        lawsuit against any of the Company and the Releasees involving any matter occurring at any time before the Release Date, Releasor waives the right to any monetary relief by virtue of filing any such charge or complaint by or on behalf of Releasor.
        This Release of Claims does not preclude Releasor from receiving an award from the U.S. Securities and Exchange Commission. In addition, this Release of Claims does not release any statutory claims that cannot be released by Releasor as a matter of
        law or public policy. Nothing in this Release is intended to effect any claim by Releasor for worker&#8217;s compensation benefits and/or unemployment compensation benefits.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Releasor acknowledges having had 21 days to consider this Release of Claims. Releasor may revoke this Release of Claims within<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>7 days of signing it. Any revocation must be made by delivering written notice of revocation to the People Team at <u>people@rocketpharma.com</u>. To be
        effective, any revocation of this Release of Claims must be in writing and received by the Company no later than the close of business on the 7th day after Releasor signs this Release of Claims. This Release of Claims shall not become effective or
        enforceable until the expiration of 7 days after Releasor signs this Release of Claims. Releasor acknowledges having had ample time to consider this Release of Claims and to consult with legal counsel concerning this Release of Claims and whether
        Releasor should sign it. Releasor has had the opportunity to negotiate the language of this Release of Claims, is satisfied with the results of that negotiation, and is signing this Release of Claims without any duress or coercion.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z41a9c94955084ddea7a036c7af98358c" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Kinnari Patel</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Date</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">13</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>EXHIBIT B</u></div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CONSULTING AGREEMENT</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Attached)</div>
    </div>
  </div>
  <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;"> <br>
    </font></div>
  <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;"> <br>
    </font></div>
  <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">14</font>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ef20055707_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 25.9.1.5330
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">




  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 10.2</font><br>
    </div>
    <div> <br>
    </div>
    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Hlk179444497"></a>ROCKET PHARMACEUTICALS, INC.</div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CONSULTING AGREEMENT</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">This Consulting Agreement (this &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Agreement</font>&#8221;) is entered into as of January 1, 2026 between Rocket Pharmaceuticals, Inc., a Delaware corporation, with an address as set forth on the signature page below (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Company</font>&#8221;), and Kinnari Patel, an individual, with an address as set forth on the signature page below (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Consultant</font>&#8221;), each herein referred to individually as a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Party</font>,&#8221; or collectively
        as the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Parties</font>.&#8221; The Parties agree that this Agreement shall not be effective until the expiration of the Revocation Period (as
        that term is defined in the Release of Claims attached as Exhibit A to the Separation Agreement and General Release between the Company and Consultant dated as of September 11, 2025) with Consultant not having revoked the Release of Claims (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Effective Date</font>&#8221;). In consideration of the mutual promises contained herein, the Parties agree as follows:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Ref204618450"></a>1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Services and Compensation</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Consultant shall perform the services described in <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Exhibit A</font>
        (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Services</font>&#8221;) for the Company, and the Company agrees to pay Consultant the compensation described in <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Exhibit A</font> for Consultant&#8217;s performance of the Services. Consultant shall perform the Services in a timely, workmanlike and professional manner and in accordance with the generally
        recognized industry standards and all applicable laws.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Ref501026921"></a>2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Confidentiality</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Definition of Confidential
          Information</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font> &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Confidential Information</font>&#8221;
        means any non-public information that relates to the actual or anticipated business and/or products, research or development of the Company, <a name="OLE_LINK5"></a><a name="OLE_LINK6"></a>its affiliates or subsidiaries, or to the Company&#8217;s, its
        affiliates&#8217; or subsidiaries&#8217; technical data, trade secrets, or know-how, including, but not limited to, research, product plans, or other information regarding the Company&#8217;s, its affiliates&#8217; or subsidiaries&#8217; products or services and markets
        therefor, customer lists and customers (including, but not limited to, customers of the Company on whom Consultant called or with whom Consultant became acquainted during the Term), software, developments, inventions, processes, formulas,
        technology, designs, drawings, engineering, hardware configuration information, marketing, finances, and other business information<font style="font-size: 10pt; font-family: 'Times New Roman';"> disclosed by the Company, </font>its affiliates or
        subsidiaries,<font style="font-size: 10pt; font-family: 'Times New Roman';"> either directly or indirectly, in writing, orally or by drawings or inspection of premises, parts, equipment, or other property of Company, </font>its affiliates or
        subsidiaries<font style="font-size: 10pt; font-family: 'Times New Roman';">.</font> Confidential Information shall also include information the Company has received and in the future will receive from third parties subject to a duty on the
        Company&#8217;s part to maintain the confidentiality of such information. Notwithstanding the foregoing, Confidential Information shall not <a name="z_Ref209263601"></a>include any such information which Consultant can establish (i) was publicly known
        or made generally available prior to the time of disclosure to Consultant; (ii) becomes publicly known or made generally available after disclosure to Consultant through no wrongful action or inaction of Consultant; or (iii) is in the rightful
        possession of Consultant, without confidentiality obligations, at the time of disclosure as shown by Consultant&#8217;s then-contemporaneous written records.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref204582655"></a>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Nonuse and Nondisclosure</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font> During and after the</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">Term, Consultant will hold in the strictest confidence, and take all reasonable precautions to prevent any unauthorized use or disclosure of
        Confidential Information, and Consultant will not (i) use the Confidential Information for any purpose whatsoever other than as necessary for the performance of the Services on behalf of the Company, or (ii) disclose the Confidential Information to
        any third party without the prior written consent of an authorized representative of Company. Consultant may disclose Confidential Information to the extent compelled by applicable law; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">provided however</font>, prior to such disclosure, Consultant shall provide prior written notice to the Company and seek a protective order or such similar confidential protection as may be available under applicable law.
        Consultant agrees that no ownership of Confidential Information is conveyed to the Consultant. Without limiting the foregoing, Consultant shall not use or disclose any Company property, intellectual property rights, trade secrets or other
        proprietary know-how of the Company to invent, author, make, develop, design, or otherwise enable others to invent, author, make, develop, or design identical or substantially similar designs as those developed under this Agreement for any third
        party. Without the Company&#8217;s prior written approval, Consultant shall not directly or indirectly disclose to anyone the existence of this Agreement or the fact that Consultant has this arrangement with the Company. Consultant agrees that
        Consultant&#8217;s obligations under this Section 2.B shall continue after the termination of this Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Other Client Confidential
          Information</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font> Consultant agrees that Consultant will not improperly use, disclose, or induce the Company to use any proprietary information or trade
        secrets of any former or concurrent employer of Consultant or other person or entity with which Consultant has an obligation to keep in confidence. Consultant also agrees that Consultant will not bring onto the Company&#8217;s premises or transfer onto
        the Company&#8217;s technology systems any unpublished document, proprietary information, or trade secrets belonging to any third party unless disclosure to, and use by, the Company has been consented to in writing by such third party.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Ref204618485"></a>3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Ownership<a name="z_Ref204618274"></a></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref501467268"></a>A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Assignment
          of Inventions</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font> Consultant agrees that all right, title, and interest in and to any copyrightable material, notes, records, drawings, designs,
        inventions, improvements, developments, discoveries and trade secrets conceived, discovered, authored, invented, developed or reduced to practice by Consultant, solely or in collaboration with others, during the Term and arising out of, or in
        connection with, performing the Services under this Agreement and any copyrights, patents, trade secrets, mask work rights or other intellectual property rights relating to the foregoing (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Inventions</font>&#8221;), are the sole property of the Company. Consultant also agrees to promptly make full written disclosure to the Company of any Inventions and to deliver and assign (or
        cause to be assigned) and hereby irrevocably assigns fully to the Company all right, title and interest in and to the Inventions.<a name="z_DV_C15"></a><a name="OLE_LINK19"></a><a name="OLE_LINK20"></a></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Pre-Existing Material</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">s.</font> Subject to Section 3.A, Consultant agrees that if, in the course of performing the Services, Consultant incorporates into any Invention or utilizes in the
        performance of the Services any pre-existing invention, discovery, original works of authorship, development, improvements, trade secret, concept, or other proprietary information or intellectual property right owned by Consultant or in which
        Consultant has an interest (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Prior Invention</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">s</font>&#8221;),
        (i) Consultant will provide the Company with prior written notice and (ii) the Company is hereby granted a nonexclusive, royalty-free, perpetual, irrevocable, transferable, worldwide license (<font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">with the right to grant and authorize sublicenses) to make, have made, use, import, offer for sale, </font><a name="z_DV_M17"></a><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">sell</font><a name="z_DV_C7"></a><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">, reproduce, distribute, modify, adapt, prepare derivative works of, display, perform, and otherwise exploit such Prior Inventions, without
          restriction, including, without limitation, as part of or in connection with such Invention, and to practice any method related thereto.</font> Consultant will not incorporate any invention, improvement, development, concept, discovery, work of
        authorship or other proprietary information owned by any third party into any Invention without Company&#8217;s prior written permission including without limitation any free software or open-source software.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Moral Rights</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font> Any assignment to the Company of Inventions includes or waives all rights of attribution, paternity, integrity, modification, disclosure and withdrawal, and any
        other rights throughout the world that may be known as or referred to as &#8220;moral rights,&#8221; &#8220;artist&#8217;s rights,&#8221; &#8220;droit moral,&#8221; or the like<a name="z_DV_C17"></a>, including, without limitation, any limitation on subsequent modification, to the extent
        permitted under applicable law.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref204618300"></a>D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Further
          Assurances</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font> Consultant agrees to assist Company, or its designee, at the Company&#8217;s expense, in every proper way to secure the Company&#8217;s rights in
        Inventions in any and all countries, including the disclosure to the Company of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments and all other instruments that the
        Company may deem necessary<font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> and testifying in a suit or other proceeding relating to such Inventions</font>. Consultant further agrees that Consultant&#8217;s obligations under
        this Section 3.D shall continue after the termination of this Agreement.<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#160;</font>Consultant agrees that, if the Company is unable for any reason, to secure
        Consultant&#8217;s signature with respect to any Inventions, then Consultant hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Consultant&#8217;s agent and attorney-in-fact, to act for and on Consultant&#8217;s
        behalf to execute and file any papers and oaths and to do all other lawfully permitted acts with respect to such Inventions. This power of attorney shall be deemed coupled with an interest<a name="z4"></a>, and shall be irrevocable.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref501026951"></a><a name="z_Ref204618573"></a><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Return
          of Company Materials. </font>Upon the termination of this Agreement, or upon Company&#8217;s earlier request, Consultant will immediately deliver to the Company, and will not keep in Consultant&#8217;s possession, recreate, or deliver to anyone else, any
        and all Company property, including, but not limited to, Confidential Information, tangible embodiments of the Inventions, all devices and equipment belonging to the Company, all electronically-stored information and passwords to access such
        property, any records maintained and any reproductions of any of the foregoing items that Consultant may have in Consultant&#8217;s possession or control.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref501026964"></a><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Term. </font>The term
        of this Agreement will begin on the Effective Date of this Agreement and will continue until December 31, 2026 <a name="z_Ref204618358"></a>(the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Term</font>&#8221;).
        Notwithstanding the foregoing, the Company may terminate this Agreement immediately and without prior notice if Consultant (i) is in breach of any material provision of this Agreement, or (ii) breaches or otherwise fails to comply with Consultant&#8217;s
        obligations to Company under the Confidentiality and Restrictive Covenant Agreement (as defined in Article 9 (Continuing Obligations) below). Upon any termination, all rights and duties of the Company and Consultant toward each other shall cease
        except: the Company will pay, within thirty (30) days after the effective date of termination, all amounts owing to Consultant prorated for Services completed and accepted by the Company prior to the termination date; and Article 2
        (Confidentiality), Article 3 (Ownership), Article 4 (Conflicting Obligations), Article 5 (Return of Company Materials), this Article 6 (Term), Article 7 (Independent Contractor), Article 8 (Indemnification), Article 9 (Continuing Obligations),
        Article 10 (Limitation of Liability), Article 11 (Arbitration and Equitable Relief), and Article 12 (Miscellaneous) will survive termination or expiration of this Agreement in accordance with their terms.<a name="z_Ref204618600"></a></div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref501026986"></a>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Independent Contractor. </font><a name="z_Ref204618618"></a><a name="z_Ref501026998"></a>Consultant shall perform the Services as an independent contractor to the Company. Nothing in this Agreement shall in any way be construed to constitute Consultant as an agent, employee or
        representative of the Company. Without limiting the generality of the foregoing, Consultant is not authorized to bind the Company to any liability or obligation or to represent that Consultant has any such authority. Consultant agrees to furnish
        (or reimburse the Company for) all tools and materials necessary to accomplish this Agreement. Consultant acknowledges and agrees that Consultant is obligated to report as income all compensation received by Consultant pursuant to this Agreement.
        Consultant agrees to and acknowledges the obligation to pay all self-employment and other taxes on such income, and the obligation and responsibility to comply with all federal, state and local laws for taxes, state compensation and disability
        insurance requirements. The Company and Consultant agree that Consultant will receive no Company-sponsored benefits from the Company such as, paid vacation, sick leave, medical insurance or 401k participation.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mutual Indemnification. </font>Consultant agrees to
        indemnify and hold harmless the Company and its affiliates and their directors, officers and employees from and against all taxes, losses, damages, liabilities, costs and expenses, including attorneys&#8217; fees and other legal expenses, arising
        directly or indirectly from or in connection with (i) any negligent, reckless or intentionally wrongful act of Consultant, (ii) any breach by the Consultant of any of the covenants contained in this Agreement, or (iii) any failure of Consultant to
        perform the Services in accordance with all applicable laws, rules and regulations.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Company agrees to indemnify and hold harmless Consultant from and against all taxes, losses, damages, liabilities, costs and expenses, including
        attorneys&#8217; fees and other legal expenses, arising directly or indirectly from or in connection with (i) any negligent, reckless or intentionally wrongful act of Company, (ii) a determination by a court or agency that the Consultant, is not an
        independent contractor, (iii) any breach by the Company of any of the covenants contained in this Agreement, (iv) any failure of Company to comply with all applicable laws, rules and regulations, or (v) any violation or claimed violation of a third
        party&#8217;s rights resulting in whole or in part from the Company&#8217;s use of the Inventions or other deliverables of Consultant under this Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref501027046"></a><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Continuing Obligations. </font>Consultant
        acknowledges and understands that Consultant remains bound and will continue to abide by Consultant&#8217;s obligations to Company pursuant to the Proprietary Information, Inventions and Non-Solicitation/Non-Competition Agreement between Consultant and
        Company (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Confidentiality and Restrictive Covenant Agreement</font>&#8221;), which shall survive execution of this Agreement according to its stated
        terms and in accordance with Paragraph 9 of the Agreement and Release between Consultant and Company. Nothing in this Agreement shall affect Consultant&#8217;s continuing obligations to Company under the Confidentiality and Restrictive Covenant
        Agreement.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref204618657"></a><a name="z_Ref501027082"></a>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Limitation of Liability. </font><a name="z_Ref204618671"></a>In no event shall Company be liable to Consultant or to any other party for any indirect, incidental, special or consequential damages, or damages for lost profits or loss of business, however caused and under any theory
        of liability, whether based in contract, tort (including negligence) or other theory of liability, regardless of whether company was advised of the possibility of such damages and notwithstanding the failure of essential purpose of any limited
        remedy. In no event shall Company&#8217;s liability arising out of or in connection with this Agreement exceed the amounts paid by Company to Consultant under this agreement for the Services, deliverables or Invention giving rise to such liability.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref501027096"></a><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Arbitration and Equitable
          Relief. </font>In consideration of Consultant&#8217;s consulting relationship with Company, its promise to arbitrate all disputes related to Consultant&#8217;s consulting relationship with the Company and Consultant&#8217;s receipt of the compensation and other
        benefits paid to Consultant by Company, at present and in the future, Consultant agrees that any and all controversies, claims, or disputes with anyone (including the Company and any employee, officer, director, shareholder or benefit plan of the
        Company in their capacity as such or otherwise), whether brought on an individual, group, or class basis, arising out of, relating to, or resulting from Consultant&#8217;s consulting relationship with the company or the termination of Consultant&#8217;s
        consulting relationship with the Company, including any breach of this agreement, shall be subject to binding arbitration under the arbitration rules set forth in the Code of Civil Procedure (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Act</font>&#8221;) and pursuant to New Jersey law. The Federal Arbitration Act shall continue to apply with full force and effect notwithstanding the application of procedural rules set forth in the
        Act. <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Disputes which Consultant agrees to arbitrate, and thereby agrees to waive any right to a trial by jury</font>, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">include any statutory claims under local, state, or federal law</font>. Consultant agrees that any arbitration will be administered by Judicial Arbitration &amp; Mediation Services, Inc. (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">JAMS</font>&#8221;) pursuant to its Employment Arbitration Rules &amp; Procedures (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">JAMS Rules</font>&#8221;). Consultant also agrees that the arbitrator shall have the power to award any remedies available under applicable law, and that the arbitrator shall award attorneys&#8217; fees and costs to
        the prevailing party, except as prohibited by law. Consultant agrees that the decree or award rendered by the arbitrator may be entered as a final and binding judgment in any court having jurisdiction thereof. To the extent that the JAMS rules
        conflict with New Jersey law, New Jersey law shall take precedence. Consultant further agrees that any arbitration under this Agreement shall be conducted in New York, New York. Except as provided by the Act and this Agreement, arbitration shall be
        the sole, exclusive, and final remedy for any dispute between Consultant and the Company. The Parties agree that any Party may also petition the court for injunctive relief where either Party alleges or claims a violation of any agreement regarding
        intellectual property, confidential information or noninterference. In the event either Party seeks injunctive relief, the prevailing party shall be entitled to recover reasonable costs and attorneys&#8217; fees.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Ref204618693"></a>11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Miscellaneous</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Governing Law</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font> This Agreement shall be governed by the laws of the State of New York, without regard to the conflicts of law provisions of any jurisdiction. To the extent that
        any lawsuit is permitted under this Agreement, the Parties hereby expressly consent to the personal and exclusive jurisdiction and venue of the state and federal courts located in New York. In any court action at law or equity that is brought by
        one of the Parties to this Agreement to enforce or interpret the provisions of this Agreement, the prevailing Party will be entitled to reasonable attorneys&#8217; fees, in addition to any other relief to which that Party may be entitled.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref505255559"></a>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Assignability</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">This Agreement will be binding upon Consultant&#8217;s heirs, executors, assigns,
          administrators, and other legal representatives, and will be for the benefit of the Company, its successors, and its assigns. </font>Except as may otherwise be provided in this Agreement, Consultant may not sell, assign or delegate any rights or
        obligations under this Agreement. Notwithstanding anything to the contrary herein, Company may assign this Agreement and its rights and obligations under this Agreement to any successor to all or substantially all of Company&#8217;s relevant assets,
        whether by merger, consolidation, reorganization, reincorporation, sale of assets or stock, or otherwise. Any attempted or purported assignment in violation of this Section 12.B shall be null and void.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Entire Agreement</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font> This Agreement constitutes the entire agreement and understanding between the Parties with respect to the subject matter herein and supersedes all prior written
        and oral agreements, discussions, or representations between the Parties, except for the Confidentiality and Restrictive Covenant Agreement, which shall continue in accordance with its stated terms. Consultant represents and warrants that
        Consultant is not relying on any statement or representation not contained in this Agreement. To the extent any terms set forth in any exhibit or schedule conflict with the terms set forth in this Agreement, the terms of this Agreement shall
        control unless otherwise expressly agreed by the Parties in such exhibit or schedule.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Severability</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font> If a court or other body of competent jurisdiction finds, or the Parties mutually believe, any provision of this Agreement, or portion thereof, to be invalid or
        unenforceable, such provision will be enforced to the maximum extent permissible so as to effect the intent of the Parties, and the remainder of this Agreement will continue in full force and effect.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">E.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Modification, Waiver.</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#160;</font>No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in a writing signed by the
        Parties. Waiver by the Company of a breach of any provision of this Agreement will not operate as a waiver of any other or subsequent breach.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref204618425"></a>F.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Notices</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font> Any notice or other communication required or permitted by this Agreement to be given to a Party shall be in writing and shall be deemed given (i) if delivered
        personally or by commercial messenger or courier service, (ii) when sent by email, or (iii) if mailed by U.S. registered or certified mail (return receipt requested), to the Party at the Party&#8217;s address written below or at such other address as the
        Party may have previously specified by like notice. If by mail, delivery shall be deemed effective three business days after mailing in accordance with this Section 12F. If to the Company, to the address for notice on the signature page to this
        Agreement, and if to Consultant, to the address for notice on the signature page to this Agreement or, if no such address is provided, to the last address of Consultant provided by Consultant to the Company.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">G.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Voluntary Nature of Agreement.</font>
        Consultant acknowledges and agrees that Consultant is executing this Agreement voluntarily and without any duress or undue influence by the Company or anyone else. Consultant further acknowledges and agrees that Consultant has carefully read this
        agreement and that Consultant has asked any questions needed for Consultant to understand the terms, consequences and binding effect of this agreement and fully understand it, including that <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Consultant is waiving their right to a jury trial</font>. Finally, Consultant agrees that Consultant has been provided an opportunity to seek the advice of an attorney of Consultant&#8217;s choice before
        signing this Agreement.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">IN WITNESS WHEREOF, the Parties have executed this Consulting Agreement as of the Effective Date.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z16aeaf5ad45e4cc0a8d433d90ce28e1d" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45%; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">KINNARI PATEL</div>
            </td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;" rowspan="1" colspan="2">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ROCKET PHARMACEUTICALS, INC.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">/s/ Kinnari Patel</div>
            </td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">/s/ Martin Wilson</div>
            </td>
          </tr>
          <tr>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 45%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Martin Wilson</div>
            </td>
          </tr>
          <tr>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 45%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">General Counsel</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zbb1e5a3c7ce74621afc705d033505638" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Address:</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Address:</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">*******</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">9 Cedarbrook Drive</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">*******</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Cranbury, NJ 08512</div>
            </td>
          </tr>

      </table>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXHIBIT A</div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SERVICES AND COMPENSATION</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Contact</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font> Consultant&#8217;s principal Company contacts are:</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-left: 90pt; font-family: 'Times New Roman'; font-size: 10pt;">Name: Martin Wilson</div>
      <div style="text-align: justify; margin-left: 90pt; font-family: 'Times New Roman'; font-size: 10pt;">Title: General Counsel and Chief Corporate Officer</div>
      <div style="text-align: justify; margin-left: 90pt; font-family: 'Times New Roman'; font-size: 10pt;">Email: *******</div>
      <div style="text-align: justify; margin-left: 90pt; font-family: 'Times New Roman'; font-size: 10pt;">Phone: *******</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-left: 90pt; font-family: 'Times New Roman'; font-size: 10pt;">Name: Gaurav Shah</div>
      <div style="text-align: justify; margin-left: 90pt; font-family: 'Times New Roman'; font-size: 10pt;">Title: CEO</div>
      <div style="text-align: justify; margin-left: 90pt; font-family: 'Times New Roman'; font-size: 10pt;">Email: *******</div>
      <div style="text-align: justify; margin-left: 90pt; font-family: 'Times New Roman'; font-size: 10pt;">Phone: *******</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Services</font>. The Services
        will include, but will not be limited to, the following:</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-left: 9pt; font-family: 'Times New Roman'; font-size: 10pt;">General consulting services as reasonably required by the Company&#8217;s Chief Executive Officer.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Compensation</font>.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company will pay Consultant an aggregate retainer fee of <a name="z_Hlk207293388"></a>$582,156 for the entirety of the Term,
        payable in 24 substantially equal semi-monthly installments, in accordance with Company&#8217;s standard payroll practices.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Consultant will retain the restricted stock units and options granted under any and all Rocket Pharmaceuticals, Inc. Stock Option, Share
        Option, and Incentive Plans (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Equity Plans</font>&#8221;). For the avoidance of doubt, Consultant&#8217;s performance of the Services shall constitute and
        be recognized as continuous service under the Equity Plans and the Award Agreements for all purposes, and Consultant shall not be considered to have a termination of employment or cessation of services under the Equity Plans or the Award Agreements
        unless and until Consultant ceases to actively perform the Services until at least December 31, 2026. Further, the termination of this Agreement upon the expiration of the Term will be considered an involuntary termination by the Company for
        purposes of the Equity Plan and the Award Agreements.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company will reimburse Consultant, in accordance with Company policy, for all reasonable expenses incurred by Consultant in
        performing the Services pursuant to this Agreement, provided that Consultant receives written consent from an authorized agent of the Company prior to incurring such expenses and submits receipts for such expenses to the Company in accordance with
        Company policy. By the fifteenth (15<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) of each month, Consultant shall submit to the Company, at <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>ap@rocketpharma.com</u></font>, a written invoice for expenses provided
        during the prior month, and such statement shall be subject to the approval of the contact person listed above or other designated agent of the Company.</div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>rckt-20250911.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.9.1.5330 Broadridge-->
<xs:schema targetNamespace="http://rocketpharma.com/20250911" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:rckt="http://rocketpharma.com/20250911" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:srt-types="http://fasb.org/srt-types/2025">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="rckt-20250911_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="rckt-20250911_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://rocketpharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>rckt-20250911_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.9.1.5330 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>rckt-20250911_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.9.1.5330 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://rocketpharma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="rckt-20250911.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://rocketpharma.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logo1.jpg
<TEXT>
begin 644 logo1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !2 ,8# 2(  A$! Q$!_\0
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MSKOP7JFI+K&I>$_AM+H]U?*"%NI(--:)G /."5.,\XQ7XP_\&E'_ "?CXO\
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MK,S--!<B%@!/ [*I:)LX!Q]Y6&3C-%?1%C8PZ99Q6]M#%;V\*A(XHD")&HZ
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MV[.>@Q[T <)^T1^TCKGPQ\=#1M)O?AK9.MB+Q(_$&L2PW-\Q+#8L<:'R4^4
M2R'!9L!>#7HWP1^)\/QJ^$/AOQ9!:R6,7B'3X;X6\C!F@+J"4)'!P<C/?%<5
MX@_9]\0V?Q;\5^(O#>O:):6OCNTM[;5X-3TIKR2 P1M$KP,LJ#!1N4<,NX9[
MD'K_ ( _"T_!'X+>&?")O1J)\.Z?%8FZ$7E>?L&-VW)VY],F@#KZ*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3"BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 11, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 11,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Rocket Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001281895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3475813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9 Cedarbrook Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cranbury<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-9100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RCKT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20055707_form8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rocketpharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ef20055707_form8k.htm">ef20055707_form8k.htm</File>
    <File>rckt-20250911.xsd</File>
    <File>rckt-20250911_lab.xml</File>
    <File>rckt-20250911_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20055707_form8k.htm": {
   "nsprefix": "rckt",
   "nsuri": "http://rocketpharma.com/20250911",
   "dts": {
    "inline": {
     "local": [
      "ef20055707_form8k.htm"
     ]
    },
    "schema": {
     "local": [
      "rckt-20250911.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "rckt-20250911_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rckt-20250911_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://rocketpharma.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20250911to20250911",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20055707_form8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250911to20250911",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20055707_form8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001140361-25-035251-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-25-035251-xbrl.zip
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M@)& 0J#(D/'1P-<]I&&X86C2C#!;AS+WZ7)76E]%09R5EHXO9-\:DR!.#*X
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M!!;T?!\ #/?SD&[TN\K?H\?M,'Y/8O$HTWBZC\)?O(!)]ND$>LJL") ?V-C
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M(F"[ 0-ML5;'/@/.3/IG&!KRC/D3N*QEHVTW08^$L="[W?4Z0_\BIP$XR/<
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MF[<;M715D%!3I:HHWK/- HASNS''##=Y;EW)U_@[\#O<5M S2T:]; [!/DF
M61Z(U2/&(03X>S_Q&G=76ML0));(Z^K%TB!TJ9!9TU#Y72O3MY7A7Q<WLDRY
M3Q(K2D;/QH8T?OOJ [J.G[?B/&A5H>\=H4=A0XW>W]6=S36PJ>95H*/[)D"I
M)9_VRN4433M8[XUA]\$JX:1+<HZCPNBBCW1VJK;\.<$E=FI.6[5S@1C'E;R@
M5RWDMX-@5^L\UP;NJ1VQZK*S@J]W^9T,S[MU;OZA/;'*&DBOVK$V,&ALGMX7
MJZ:LV'[S5*R> ,J!K9V:E-$:0PE%&3SSC)^9YLXJ#7Y<C%Q!I,\^O+4I5M\&
M#J61>*OE4+?@L;4E5@_+H:Y++W./08)S"M(YZ!YJ9-J-N5>VQ>H[,-A5EG'-
MW1IC$YCOUX@DD;95=MI%Q9REMSF(+FF0*)_"<=O]S84Y$@]7V6<DY;/][Y5]
MWWSHX,ZZT[VK1_OWH![U<Y2-GNBSIZ"M9WTFH,'Q _/CI[4$LHD5?A&)6T1+
M[:<"[XGQ5O4VG3/NPAOVY6/B<5TV[,"G/W2-[H/0:4.SDZ]B8#/)5526WRWT
MBE;46_=CJJMUW34/XL2<BLRIP+^"J6>ZU2C*>'DRRWQ)E_%IZ@PFM\S>6A)7
ML6ZFJON+1PKTW.6Z"HRC58J#Z.F0$H["9<&6UDATUT61V2X>1I0%-7YL=:&L
MQC+XEGLN6D2"L9=,I6/KF.I/K-?.<<CP@IT7)9TDQL6GRCB*@_Y9KGM!G/,S
M@RTUT@:OHG7=6C96&(4C6"["):X<P)Y>N)!*9:-U1BQG*)AR2/F!RQM-*P%<
MN^\2%HR&7Z&+"AOP&0QHJ:XXT4AA<[YL@ VOC(LL*[#""GM<<:4E3FA_CP!$
M^J*N#'Z%J< F'D$>#%UR8M8&]8%<H%$&;2';S@[;)")W"O0Z;8K,]B&0S @]
MCJ:%A)^ \992:74JKJ4-8E4ZN0+A+#%'"*T+W*M?,.QW=W/KBMM04)L@[!#Q
M+R$4GMZ#4'C'C1U;FJ03"GU4$:(-O\7(0>7.V%Z7BD?ZG,Q!0Q2#_MIV;2DP
MD3MR.ELF;3"%&87$J HS(T;RK. ..ZF< G/'+PSWI-A14MA.0B9P%<63K)/7
M=2T:*;,RXTM68P"-?]/DE/O]+Z@1I/7V)PJAL4N-L-08<(R$$;QT11 SV8SD
M+:,*R;#[1KM?!AF].)(QFITUY#,=([=58NS2L'5G1[A:<]H,C=8SUY3'IF0G
M:306]#V:>D\W/MAXDQEP@\AL,FD2HQ\?Y78;.=Z&^&%X[&$0-W#FW@V#EX^X
MQIO+6"M2%5I^F%E&B<X4DD05+9F[B&F$]%:-RF,6U-4G!P$6MPDDJASX/.I8
MU=<]E.&4M[:D_C2,9Z(S U_K(G/:7H)-@F$EP9<C;*O94_C<CK*#&F%ZMU.V
M,]9D\+E2'F-;]+JWFTIU'?<^4&P"#+BCJL45^NID'B,M]Q@R3\'4>2BW]K.[
MIJ;T>V]ZY'+ #-IZ-9T)N72[RC6H>,B28)U-GO9XM5'Y'6)>=7]#I05^TEC3
M5N(L2"F-0D:MBIW3(E^_*(!8C _J"7Y!#9)KW6KA;=MUAYI)GH9Z/"_E:S3@
M_US7<*>(BHN5V<2U3K(H+Z4=C2 Y:QRIJ&&1SA] @YQC8D%SW3-9@DB3LXDX
ML%0?!SK:+=)CF'^ZM2[)+=R'1XE'\WMSO0<.SELXT8/V]D+7R=[3A:Z3IYO/
MMK^[![^[!^]-S!S<@R6X( )PNW_PJ4D1.<'B'\%=JICF+?T.%6FV6;O+8&'S
M%&P2&I44V*PIJY22UDM$3QX/S,'C7C+4:X!27C5URC5*-&9!\&<:"I1LBBJ1
MPX'_)L7%=D,=V%Y(7!":>K%IBAU44889QB/OG$-FK6CE0UFQNFCU3\Q[*NN@
M9:W3FA.UYK4I'KTU*#?A9;5ZY*9(;"P.77SIM:XH0XNX(B846&^1[95I08"[
MR?LBNUY]Q0:UINN2:>=E-&.3^A'Z1T$7G=,5$?U'[9BZ=V#&5=@+3(N6R, 8
MI+DPP\8*R2$TG(>Z=K_J*:,N07&=9*R\!O5!8JSYJ@[-)<$$0K>';T:)/7@P
M)79K\_-+(19&"D/9P4%#QV'Z+A_IUQFL<</IJO W%C*9X+XQ-9'BS74EQ&C,
M>MAKC.5D#;JA7#56\=DS+8ZV>V,,':&SVEN9+5=LJX.7<XT2OL=([K&?<K-M
M#*#3IG=A47&<78UI1T ,%3L;Z#*:@>E0QH Q^8V41;8:IV"'F\;_M8XZY[\;
M.)_> #E$J=!!PNU\S!:I#[D!2U=UYPUI9,HSF1 ?X52N*+EC+># 5.M1"P)K
M=+45*@S<D(QT'>35.O"#V.X00=KS@ M"[+F3J7P7U+ LN^C-7KXM!^53L2YR
M97I'A[42I/=;N"S4H$<S1I_HS8!0O:X=?LM>"W\CF+9MHU-V@ "P,[3T$I6B
M4%F^X768=.Z&HX3 P!C%87\!?%=SJG"AP,8;#J1$K J&:F>@(_.8.;\.-:8
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M]VSP('B)RIA-*<.!92M284-F!&AWNTP8N^GIW3*(>P&WVKWD14X5-R-8#N'
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M//- 7-@4!GNC*L@HYOH(>>=/CULS^&N1-3D5!IWR*0+8PWH-XFK]Y?F?WC_
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MD]/3P_,3<79X>?PV/D%[JG7ZT6TMWI5E.U\RB"B+&\"A_(>5K14\#/Z\_;5
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MUW!W%M_R-$-$I^3+Y3[F9!9/%=DG#QW00'819JQSUI2#PMF25^K!'I':6KK
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M-]&Y4GFKIIZ20>/!FC6J#W0FQR;Z8/VT;D9R^WYYM%>*."16)A24"E3=2AZ
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MQ,^U/_P/4$L! A0#%     @ ]X$Q6[&^$,V[/   &#$! !4
M ( !     &5F,C P-34W,#=?97@Q,"TQ+FAT;5!+ 0(4 Q0    ( />!,5O(
M'O9=@"@  '7.   5              "  >X\  !E9C(P,#4U-S W7V5X,3 M
M,BYH=&U02P$"% ,4    " #W@3%; *RE5%(5  #JAP  %0
M@ &A90  968R,# U-3<P-U]F;W)M.&LN:'1M4$L! A0#%     @ ]X$Q6X/2
M$KI& P  10\  !$              ( !)GL  ')C:W0M,C R-3 Y,3$N>'-D
M4$L! A0#%     @ ]X$Q6ZY(87=Z"   ,%8  !4              ( !FWX
M ')C:W0M,C R-3 Y,3%?;&%B+GAM;%!+ 0(4 Q0    ( />!,5N<K^*MWP4
M /D^   5              "  4B'  !R8VMT+3(P,C4P.3$Q7W!R92YX;6Q0
52P4&      8 !@". 0  6HT

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>ef20055707_form8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rckt-20250911.xsd" xlink:type="simple"/>
    <context id="c20250911to20250911">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
        </entity>
        <period>
            <startDate>2025-09-11</startDate>
            <endDate>2025-09-11</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20250911to20250911"
      id="Fact_9bcfb881f8e94d74a5a027f1da2b1e53">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20250911to20250911"
      id="Fact_06a43207b6ce4c0d988be10a32a069c8">0001281895</dei:EntityCentralIndexKey>
    <dei:EntityAddressStateOrProvince
      contextRef="c20250911to20250911"
      id="Fact_30b23652e8ee423595f74a59892f1be5">NJ</dei:EntityAddressStateOrProvince>
    <dei:DocumentType
      contextRef="c20250911to20250911"
      id="Fact_543cc8cde36c4bf18cfaa8a59359d0cd">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20250911to20250911"
      id="Fact_93d2aee26f3443e9bbdb130030f8d6fc">2025-09-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20250911to20250911"
      id="Fact_0af8903f06904ffb86fd446d2b032f00">Rocket Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20250911to20250911"
      id="Fact_77662285ac764c3988378b13d79742ef">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20250911to20250911"
      id="Fact_d8069a2330b84b24b7e53e2d4f2294ea">001-36829</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20250911to20250911"
      id="Fact_189912fd0d804b9dacd1b0d43cd69eb0">04-3475813</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20250911to20250911"
      id="Fact_f22ee553e2e44a959a8a108829e76a67">9 Cedarbrook Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20250911to20250911"
      id="Fact_e713e50c676b44f7ae07da274d27245c">Cranbury</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="c20250911to20250911"
      id="Fact_ac0cdb1d754d4c2b9a11ecc5973be7cd">08512</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20250911to20250911"
      id="Fact_339588db56884c908766063c7246977d">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20250911to20250911"
      id="Fact_f3fe47ba63144baab0b1cae69d070eaf">440-9100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20250911to20250911"
      id="Fact_2aa0ea434fca473896c21f4911ef3c63">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20250911to20250911"
      id="Fact_da7488ecc6b34320b8c343d784507648">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20250911to20250911"
      id="Fact_8c3defdcfc3940018c783e94d8049b6c">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20250911to20250911"
      id="Fact_48186a54a7a74c1eba6e2c97e9c3276c">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20250911to20250911"
      id="Fact_173e410f99984b92bd302dc9809d9be5">Common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20250911to20250911"
      id="Fact_ecad95df0e2e449a9032f25aa73bd669">RCKT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20250911to20250911"
      id="Fact_436686f0c9cf4eb8820d422c99e3a363">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20250911to20250911"
      id="Fact_173c626f573e4597b2567da370616b33">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
